After President Trump Gets Experimental Antibody Cocktail, Is Regeneron Stock a Good Coronavirus Buy?
There's been a lot of focus on clinical stage biotech companies and the coronavirus vaccine race over the past few months. But President Donald Trump's recent COVID-19 diagnosis has thrown one particular biotech into the spotlight: Regeneron Pharmaceuticals (NASDAQ: REGN). Trump was administered Regeneron's investigational antibody cocktail and called it "a cure." Since the cocktail hasn't yet been approved for public use by the U.S. Food and Drug Administration (FDA), doctors were only able to offer it to Trump after his doctors made a "compassionate use" request.
Now, Regeneron is seeking an emergency use authorization (EUA) for the cocktail, known as REGN-COV2. In a statement on Twitter, Trump said that he would do everything possible to get the treatment to other COVID-19 patients as soon as possible. The president also said that the federal government would make it free to Americans and take care of distribution. With Trump championing Regeneron and the world eager for new treatment options, it's easy to feel optimistic about the company's prospects. But is Regeneron really heading toward victory? And should it be your next coronavirus buy? Let's find out.
Image source: Getty Images.
Source Fool.com
